Abbott Laboratories (ABT)vsEdwards Lifesciences Corp (EW)
ABT
Abbott Laboratories
$105.64
+0.24%
HEALTHCARE · Cap: $177.07B
EW
Edwards Lifesciences Corp
$89.60
+0.88%
HEALTHCARE · Cap: $49.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 615% more annual revenue ($46.59B vs $6.51B). EW leads profitability with a 15.4% profit margin vs 11.7%. ABT appears more attractively valued with a PEG of 2.01. EW earns a higher WallStSmart Score of 55/100 (C).
ABT
Buy52
out of 100
Grade: C-
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-46.2%
Fair Value
$73.35
Current Price
$105.64
$32.29 premium
Margin of Safety
+69.3%
Fair Value
$257.97
Current Price
$89.60
$168.37 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.2x leaves little room for execution misses.
Key Dynamics to Monitor
ABT profiles as a value stock while EW is a mature play — different risk/reward profiles.
EW carries more volatility with a beta of 0.85 — expect wider price swings.
EW is growing revenue faster at 13.6% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 52/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?